Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

A new and as yet unpublished study has raised increased concern about the relationship between rofecoxib (Vioxx), Merck’s blockbuster COX-2 inhibitor, and cardiovascular events.

Pharmacology Watch: Linking COX-2 Inhibitors and Cardiovascular Event Risk